Sera Prognostics Inc. (SERA)
6.38
0.05 (0.79%)
At close: Jan 14, 2025, 3:59 PM
6.37
-0.23%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 5.87 |
| Market Cap | 209.46M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.99 |
| PE Ratio (ttm) | -6.45 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 10.19 |
| Volume | 119,935 |
| Avg. Volume (20D) | 101,181 |
| Open | 6.40 |
| Previous Close | 6.33 |
| Day's Range | 6.03 - 6.58 |
| 52-Week Range | 4.98 - 12.36 |
| Beta | undefined |
About SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, g...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Jul 15, 2021
Employees 55
Stock Exchange NASDAQ
Ticker Symbol SERA
Website https://seraprognostics.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SERA stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Sera Prognostics Inc. is scheduled to release its earnings on Mar 19, 2025,
during market hours.
Analysts project revenue of $15.00K, reflecting a -63.41% YoY shrinking and earnings per share of -0.24, making a -4.00% decrease YoY.
Analysts project revenue of $15.00K, reflecting a -63.41% YoY shrinking and earnings per share of -0.24, making a -4.00% decrease YoY.
